Economic impact of mechanical cardiac assistance

Progress in Cardiovascular Diseases

Volumn 43, Issue 1, 2000, Pages 81-94

  Evans, Roger W ^a,b  

^a MN ^*  (United States)

^b PhD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSISTED CIRCULATION; CAPITATION FEE; COST EFFECTIVENESS ANALYSIS; DEVICE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL BILLING; HUMAN; REIMBURSEMENT; REVIEW;

EID: 0033926238     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2000.7201     Document Type: Article

References (110)

1. Evans RW. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. Terasaki PI, Cecka JM. Clinical Transplants, 1993. 1994;359-391 UCLA Tissue Typing Laboratory, Los Angeles, CA
2. Evans RW. Coverage and reimbursement for heart transplantation. Int J Technol Assess Health Care. 2:1986;425-449
3. Evans RW. The economics of heart transplantation. Circulation. 75:1987;63-76
4. Garrison LP Jr, Evans RW. The economic impact of heart transplantation on the Medicare program, 1985-89. Baumgartner WG, Reitz BA. Heart and Heart-Lung Transplantation. 1989;41-50 Williams and Wilkins, Baltimore, MD
5. Reemtsma K, Berland G, Merrill J, et al. Evaluation of surgical procedures, changing patterns of patient selection, and costs in heart transplantation. J Thorac Cardiovasc Surg. 104:1992;1308-1313
6. Evans RW. Social, economic, and insurance issues in heart transplantation. O'Connell JB, Kaye MP. Intrathoracic Transplantation 2000. 1993;1-17 RG Landes, Austin, TX
7. Evans RW. Socioeconomic aspects of heart transplantation. Curr Opin Cardiol. 10:1995;169-179
8. Sharples LD, Briggs A, Caine N, et al. A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation. 62:1996;615-621
9. Evans RW. Health care technology and the inevitability of resource allocation and rationing decisions (First of two parts). JAMA. 249:1983;2047-2053
10. Evans RW. Health care technology and the inevitability of resource allocation and rationing decisions (Second of two parts). JAMA. 249:1983;2208-2219
11. Dean M. Is your treatment economic, effective, and efficient? Lancet. 337:1991;480-481
12. Caplan AL. If I Were a Rich Man Could I Buy a Pancreas? 1992;Indiana University Press, Bloomington, IN
13. Ubel PA. Can we continue to afford organ transplants in an era of managed care? Am J Managed Care. 2:1996;293-297
14. Asch DA, Ubel PA. Rationing by any other name. N Engl J Med. 336:1997;1668-1671
15. Robinson R. Rationing health care: A national framework and local discretion. J Health Serv Res Policy. 2:1997;67-70
16. Lamm RD. Marginal medicine. JAMA. 280:1998;931-933
17. Feek CM, McKean W, Henneveld L, et al. Experience with rationing health care in New Zealand. Br Med J. 318:1999;1346-1348
18. Smith R, Hiatt H, Berwick D. Shared ethical principles for everybody in health care: A working draft from the Tavistock Group. Br Med J. 318:1999;248-249
19. Dolan P, Cookson R, Ferguson B. Effect of discussion and deliberation on the public's views of priority setting in health care: Focus group study. Br Med J. 318:1999;916-919
20. Evans RW. Organ transplantation costs, insurance coverage, and reimbursement. Terasaki PI. Clinical Transplants, 1990. 1990;343-355 UCLA Tissue Typing Laboratory, Los Angeles, CA
21. Evans RW. Third party payment and the cost of transplantation. J South Carolina Med Assoc. 87:1991;345-352
22. Roper WL. Medicare Program; Criteria for Medicare Coverage of Heart Transplants: Final Notice. Federal Register. 52:1987;10935-10951
23. Steinberg EP, Tunis S, Shapiro D. Insurance coverage for experimental technologies. Health Aff (Millwood). 14:1995;143-158
24. Finkelstein BS, Silvers JB, Marrero U, et al. Insurance coverage, physician recommendations, and access to emerging treatments. JAMA. 279:1998;663-668
25. Sabin JE, Daniels N. Making insurance coverage for new technologies reasonable and accountable. JAMA. 279:1998;703-704
26. Priester R, Gervais KG, Vawter DE. A model for improving coverage policy decisions. Am J Managed Care. 5:1999;981-991
27. Frick KD, Lyles A, Powe NR. To cover or not to cover: How to decide? Am J Managed Care. 5:1999;1064-1066
28. Rose EA, Goldstein DJ. Wearable long-term mechanical support for patients with end-stage heart disease: A tenable goal. Ann Thorac Surg. 61:1996;399-402
29. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med. 339:1998;1522-1533
30. DeVries WC, Anderson JL, Joyce LD, et al. Clinical use of the total artificial heart. N Engl J Med. 310:1984;273-278
31. Copeland JG, Levinson MM, Smith RG, et al. The total artificial heart as a bridge to transplantation: A report of two cases. JAMA. 256:1986;2991-2995
32. Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: Bridge to transplantation and the future. Ann Thorac Surg. 47:1989;142-150
33. Hogness JR, VanAntwerp M. The Artificial Heart: Prototypes, Policies, and Patients. 1991;National Academy Press, Washington, DC
34. Frazier OH, Duncan JM, Radovancevic B, et al. Successful bridge to heart transplantation with a new left ventricular assist device. J Heart Lung Transplant. 11:1992;530-537
35. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg. 53:1992;1080-1090
36. McCarthy PM, Sabik JF. Implantable circulatory support devices as a bridge to transplantation. Semin Thorac Cardiovasc Surg. 6:1994;181-187
37. Pennington DG, McBride LR, Peigh PS, et al. Eight years' experience with bridging to cardiac transplantation. J Thorac Cardiovasc Surg. 107:1994;472-480
38. Mehta SM, Aufiero TX, Pae WE Jr, et al. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation: Sixth official report-1994. J Heart Lung Transplant. 14:1995;585-593
39. Catanese KA, Goldstein DJ, Williams DL, et al. Outpatient left ventricular assist device support: A new destination rather than a bridge. Ann Thorac Surg. 61:1996;399-402
40. Jacquet L, Dion R, Noirhomme P, et al. Successful bridge to retransplantation with the wearable Novacor left ventricular assist system. J Heart Lung Transplant. 15:1996;620-622
41. Copeland JG, Pavie A, Dureau D, et al. Bridge to transplantation with the CardioWest total artificial heart: The international experience: 1993 to 1995. J Heart Lung Transplant. 15:1996;94-99
42. Mussivand T, Eng D, Hendry PJ, et al. Development of a ventricular assist device for out-of-hospital use. J Heart Lung Transplant. 18:1999;166-171
43. Evans RW, Manninen DL, Garrison LP Jr, et al. Donor availability as the primary determinant of the future of heart transplantation. JAMA. 255:1986;1892-1898
44. Evans RW, Orians CE, Ascher NL. The potential supply of organ donors: An assessment of the efficiency of organ procurement efforts in the United States. JAMA. 267:1992;239-246
45. Touraine JL, Traeger J, Betuel H, , et al. Organ Shortage: The Solutions. 1995;Kluwer Academic, Boston, MA
46. Rettig RA, Levinsky NG. Kidney Failure and the Federal Government. 1991;National Academy Press, Washington, DC
47. Iglehart JK. The American health care system: The End-Stage Renal Disease Program. N Engl J Med. 328:1993;366-371
48. Nissenson AR, Rettig RA. Medicare's End-Stage Renal Disease Program: Current status and future prospects. Health Aff (Millwood). 18:1999;161-179
49. Aaron JH, Schwartz WB. The Painful Prescription: Rationing Hospital Care. 1984;The Brookings Institution, Washington, DC
50. Schwartz WB, Aaron HJ. Rationing hospital care: Lessons from Britain. N Engl J Med. 310:1984;52-56
51. Kingman S. Renal services in U.K. are underfunded, says report. Br Med J. 312:1996;267
52. Finkler SA. The distinction between cost and charges. Ann Intern Med. 96:1982;102-109
53. Finkler SA. Issues in Cost Accounting for Health Care Organizations. 1994;Aspen Publications, Gaithersburg, MD
54. Clement JP. Dynamic cost shifting in hospitals: Evidence from the 1980s and 1990s. Inquiry. 34:1998;340-350
55. Balas EA, Kretschmer RAC, Gnann W, et al. Interpreting cost analyses of clinical interventions. JAMA. 279:1998;54-57
56. Evans RW. Effect of liver transplantation on local, regional, and national health care. Busuttil RW, Klintmalm GB. Transplantation of the Liver. 1996;869-879 Saunders, Philadelphia, PA
57. Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation: Costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am. 22:1993;451-473
58. Evans RW. The socioeconomics of organ transplantation. Transplant Proc. 17:(suppl 4):1985;129-136
59. Evans RW. Cost-effectiveness analysis of organ transplantation. Surg Clin North Am. 66:1968;603-616
60. Evans RW. A catastrophic disease perspective on organ transplantation. Ginzberg E. Medicine and Society: Clinical Decisions and Societal Values. 1987;61-95 Westview Press, Boulder, CO
61. Evans RW. Liver transplantation in a managed care environment. Liver Transpl Surg. 1:1995;61-75
62. Evans RW. Organ transplantation in an era of economic constraint: Liver transplantation as a case study. Semin Anesthesiol. 14:1995;127-135
63. Evans RW, Kitzmann DJ. Contracting for services: Liver transplantation in the era of mismanaged care. Clin Liver Dis. 1:1997;287-303
64. Staniforth AD, Crowley AJ. Chronic heart failure: Interventions and outcomes. Dis Manage Health Outcomes. 1:1997;185-196
65. Rose EA, Stevenson LW. Management of End-Stage Heart Disease. 1998;Lippincott-Raven Press, Boston, MA
66. Hauboldt RH. Cost Implications of Human Organ Transplantation, An Update: 1993. 1993;Milliman & Robertson, Brookfield, WI
67. Hauboldt RH. Cost Implications of Human Organ and Tissue Transplantation, An Update: 1996. 1996;Milliman & Robertson, Brookfield, WI
68. Haubloldt RH, Courtney TD. Cost Implications of Human Organ and Tissue Transplantation, An Update: 1999. 1999;Milliman & Robertson, Brookfield, WI
69. Evans RW. Organ procurement expenditures and the role of financial incentives. JAMA. 269:1993;3113-3118
70. Towery OB, Perry S. The scientific basis for coverage decisions by third party-payers. JAMA. 245:1981;59-61
71. Schaffarzick RW. Technology assessment: Perspective of a third party payer. Lohr KN, Rettig RA. Quality of Care and Technology Assessment. 1987;98-105 Institute of Medicine, National Academy of Sciences, Washington, DC
72. Conrad D, Bonney R, Sachs M, et al. Managed Care Contracting: Concepts and Applications for the Health Care Executive. 1996;Health Administration Press, Chicago, IL
73. Todd MK. The Managed Care Contracting Handbook. 1997;McGraw Hill, Burr Ridge, IL
74. Ascher NL, Evans RW. Designation of liver transplant centers in the United States. Transplant Proc. 19:1987;2405
75. Evans RW. Public and private insurer designation of transplantation programs. Transplantation. 53:1992;1041-1046
76. Evans RW. Left ventricular assist devices: Permanent implant versus bridge to transplantation-is either cost-effective? J Heart Lung Transplant. 16:1997;1180-1185
77. Bodenheimer T. Disease management-promises and pitfalls. N Engl J Med. 340:1999;1202-1205
78. Kesteloot K. Disease management: A new technology in need of critical assessment. Int J Technol Assess Health Care. 15:1999;506-519
79. Kannell WB. Epidemiological aspects of heart failure. Cardiol Clin. 7:1989;1-9
80. Massie BM, Packer M. Congestive heart failure: Current controversies and future prospects. Am J Cardiol. 66:1990;429-430
81. Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 20:1992;301-306
82. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 126:1993;1042-1047
83. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant. 13:1994;5107-5112
84. Robbins MA, O'Connell JB. Economic impact of heart failure. Rose EA, Stevenson LW. Management of End-Stage Heart Disease. 1998;3-11 Lippincott-Raven, Philadelphia, PA
85. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: A population-based study. J Natl Cancer Inst. 91:1999;847-853
86. Wagner JL, Alberts SR, Sloan JA, et al. Correspondence: erratum. J Natl Cancer Inst. 92:2000;164-165
87. Page L. Insurance coverage for clinical trials. Am Med News. 41:1998;3
88. Rosenbaum S, Frankford DM, Moore B, et al. Who should determine when health care is medically necessary? N Engl J Med. 340:1999;229-232
89. Weisbrod BA, La May CL. Mixed signals: Public policy and the future of health care R & D. Health Aff (Millwood). 18:1999;112-125
90. Landers SJ. Physicians urge Medicare coverage of cancer clinical trials. Am Med News. 42:(33):1999;5-6
91. Gelijns AC. Technology and Health Care in an Era of Limits. 1992;National Academy Press, Washington, DC
92. Sheingold SH. Technology assessment, coverage decisions, and conflict: The role of guidelines. Am J Managed Care. 4:1998;SP117-SP125
93. Ramsey SD, Luce BR, Deyo R, et al. The limited state of technology assessment for medical devices: Facing the issues. Am J Managed Care. 4:1998;SP188-SP199
94. Goodman CS. Healthcare technology assessment: Methods, framework, and role in policy making. Am J Managed Care. 4:1998;SP200-SP213
95. Mowatt G, Bower DJ, Brebner JA, et al. When is the "right" time to initiate an assessment of a health technology. Int J Technol Assess Health Care. 14:1998;372-386
96. Solomon DK, Gourley DR, Brown JR, et al. Technology assessment and drug use process. Am J Managed Care. 5:1999;220-229
97. Haynes B. Can it work? Does it work? Is it worth it? Br Med J. 319:1999;652-653
98. Green J, Wintfield N, Krasner M, et al. In search of America's best hospitals: The promise and reality of quality assessment. JAMA. 277:1997;1152-1155
99. Herzlinger RE. Market-Driven Health Care. 1997;Addison-Wesley, Boston, MA
100. Chen J, Radford MJ, Wang Y, et al. Performance of the "100 top hospitals": What does the report card report? Health Aff (Millwood). 18:1999;53-68
101. Chen J, Radford MJ, Wang Y, et al. Do "American's Best Hospitals" perform better for acute myocardial infarction? N Engl J Med. 340:1999;286-292
102. Finlayson SRG, Birkmeyer JD, Tosteson A, et al. Patient preferences for location of care: Implications for regionalization. Med Care. 37:1999;204-209
103. Plogman PL, Pine M, Reed DC, et al. Anthem Blue Cross and Blue Shield's Coronary Service's Network: A managed care organization's approach to improving the quality of cardiac care for its members. Am J Managed Care. 4:1998;1679-1686
104. American Heart Association. Economic Cost of Cardiovascular Diseases. http://www.americanheart.org/statistics/10econom.html:;. Available at
105. Evans RW. Need, demand, and supply in organ transplantation. Transplant Proc. 24:1992;2152-2154
106. Evans RW. Cardiac replacement: Need, demand, and supply estimation. Rose EA, Stevenson LW. Management of End-Stage Heart Disease. 1998;13-24 Lippincott-Raven Press, Boston, MA
107. Evans RW. Coming to terms with reality: Why xenotransplantation is a necessity. (in press):
108. United Network for Organ Sharing: 2000. http://www.unos.org:2000;. Available at
109. Publication No. 03409 Health Care Financing Review Medicare and Medicaid Statistical Supplement, 1998. December 1998
110. Levit K, Cowan C, Lazenby H, et al. Health spending in 1998: Signals of change. Health Affairs. 19:2000;124-132